Galectin Therapeutics Inc. (GALT)

1.3000

-0.0700

(-5.11%)

At close: 4:00:01 PM EDT

1.3000

0.00

(0.00%)

After hours: 4:20:01 PM EDT

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress

NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the EASL 2025 meeting and deliver a scientific presentation in the late-breaking oral presentation session. The meeting will be held May 7-10, 2025, in Amsterdam, Netherlands. “We are excited that data from our NAVIGATE study, evaluating belapectin, a g

GlobeNewswire 16 days ago

GALT
-5.11%
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Here is how ANI Pharmaceuticals (ANIP) and Galectin Therapeutics Inc. (GALT) have performed compared to their sector so far this year.

Zacks 24 days ago

ANIP

GALT
-5.11%
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “In the U.S. approximately 5 million adults are affected by MASH cirrhosis and clinically significant portal hypertension. The need for new treatments tha

GlobeNewswire last month

GALT
-5.11%
While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership

Key Insights Galectin Therapeutics' significant individual investors ownership suggests that the key decisions are...

Simply Wall St. last month

GALT
-5.11%
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs placebo in per-protocol patients (completers) enrolled in the U.S.New estimates indicate around 3 million adults in the U.S. suffer from MASH cirrhosis and clinically significant portal hypertension1, for which there are no FDA approved therapiesFull analysis of the NAVIGATE trial is ongoing; additional data, including from patients comp

GlobeNewswire 2 months ago

GALT
-5.11%
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented during the 2025 MASH-TAG Conference, being held January 9-11, 2025 in Park City, Utah. Additionally, Company’s executive leadership will be hosting one-on-one meetings in San Franscico January 13-16,

GlobeNewswire 3 months ago

GALT
-5.11%
Top Midday Decliners

Cyngn (CYN) said Friday that it priced a follow-on offering and plans to use the gross proceeds of a

PREMIUM
MT Newswires 4 months ago

CYN

GALT
-5.11%
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placeboWhile there was a favorable trend for incidence of varices in the primary end point intent-to-treat population, belapectin did not achieve statistical significanceBelapectin was overall well tolerated with no safety signals; incidence of adverse events and serious adverse events were comparable across the t

GlobeNewswire 4 months ago

GALT
-5.11%
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks

The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 4 months ago

GALT
-5.11%
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosisBlinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, facilitating utilization of this outcome as a critical endpoint in portal hypertension trialsApproximately a third of patients with MAS

GlobeNewswire 5 months ago

GALT
-5.11%
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin

GlobeNewswire 5 months ago

GALT
-5.11%
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD)’s annual meeting, 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, C

GlobeNewswire 6 months ago

GALT
-5.11%
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference

NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024. Dr. Jamil will be sharing the latest updates on clinical programs and pipeline advancement on October 7, 2024 at 10:00 AM ET. The webcast of

GlobeNewswire 6 months ago

GALT
-5.11%
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Dr. Jamil will be providing a company presentation on September 9, 2024 at 12:00 PM ET. The webcast of t

GlobeNewswire 7 months ago

GALT
-5.11%
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, “We continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first ha

GlobeNewswire 8 months ago

GALT
-5.11%
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in

GlobeNewswire 8 months ago

GALT
-5.11%
Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%

Key Insights Significant control over Galectin Therapeutics by retail investors implies that the general public has...

Simply Wall St. 8 months ago

GALT
-5.11%
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy. “At this year’s meeting we are again pleased to share important scientific information with the hepatology community. Through the knowledge captured from our belapectin program, we are adding

GlobeNewswire 10 months ago

GALT
-5.11%
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today re

GlobeNewswire 11 months ago

GALT
-5.11%
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference

NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. Detailed information about the presentation is below. H.C. Wainwright 2nd Annual BioConnect Investor Conference Format: Fireside chat Date and time: May 20, 2024 at 4:00 PM ET Location: Nasdaq World Headquarters,

GlobeNewswire 11 months ago

GALT
-5.11%

Performance Overview

Return	GALT	S&P 500 (^GSPC)
YTD	+0.78%	-4.72%
1-Year	-62.86%	+11.67%
3-Year	-16.13%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Top Midday Decliners

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference

Performance Overview